Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 1.08 -0.02 (-1.82%) Market Cap: 276.01 Mil Enterprise Value: 161.16 Mil PE Ratio: 0 PB Ratio: 11.58 GF Score: 70/100

Q1 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript

May 09, 2022 / 12:00PM GMT
Release Date Price: $1.54 (-9.94%)
Operator

Good morning, and thank you for standing by. Welcome to the First Quarter 2022 Adaptimmune Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Juli Miller, Head of Investor Relations. Please go ahead.

Juli P. Miller
Adaptimmune Therapeutics plc - VP of IR

Good morning, and welcome to Adaptimmune's conference call to discuss our first quarter 2022 financial results and business updates. I would ask you to review the full text of our forward-looking statements from this morning's press release. We anticipate making projections during this call and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC.

Adrian Rawcliffe, our Chief Executive Officer; and Gavin Wood, our Chief Financial Officer, are here with me for the prepared portion of the call. Other members of our management team will be available for Q&A.

With that, I'll turn the call

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot